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Lung cancer has been the leading cause of cancer death 
worldwide [1], and adenocarcinoma is the most common 
histologic subtype of primary lung cancer [2]. Recently, 
the therapeutic strategies for lung cancer have been 
 developing and shifting from cytotoxic reagents to 
molecular- targeted reagents. However, the evolving mecha-
nisms through which cancer cells are resistant to these 
drugs have emerged as some of the most challenging 
properties of cancer to overcome. Epithelial- mesenchymal 
transition (EMT) and cancer stemness (CS) are known 
to be pivotal for driving metastasis, recurrence, and re-
sistance for treatment in lung cancer, but the nature of 
these factors is not completely understood.
EMT is a critical event not only in embryonic develop-
ment and in cell migration during wound healing or tissue 
development [3, 4], but also in the migration of malignant 
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Abstract
The epithelial- mesenchymal transition (EMT) and cancer stemness (CS) are 
reported to be pivotal phenomena involved in metastasis, recurrence, and drug- 
resistance in lung cancer; however, their effects on tumor malignancy in clinical 
settings are not completely understood. The mutual association between these 
factors also remains elusive and are worthy of investigation. The purpose of 
this study was to elucidate the association between EMT and CS, and their 
effect on the prognosis of patients with lung adenocarcinoma. A total of 239 
lung adenocarcinoma specimens were collected from patients who had undergone 
surgery at Kyoto University Hospital from January 2001 to December 2007. 
Both EMT (E- cadherin,vimentin) and CS (CD133, CD44, aldehyde dehydroge-
nase) markers were analyzed through immunostaining of tumor specimens. The 
association between EMT and CS as well as the patients’ clinical information 
was integrated and statistically analyzed. The molecular expression of E- cadherin, 
vimentin, and CD133 were significantly correlated with prognosis (P = 0.003, 
P = 0.005, and P < 0.001). A negative correlation was found between E- cadherin 
and vimentin expression (P < 0.001), whereas, a positive correlation was found 
between vimentin and CD133 expression (P = 0.020). CD133 was a stronger 
prognostic factor than an EMT marker. Elevated CD133 expression is the sig-
nature marker of EMT and CS association in lung adenocarcinoma. EMT and 
CS are associated in lung adenocarcinoma. Importantly, CD133 is suggested to 
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cells undergoing invasion and metastasis [4–6]. EMT is 
composed of two processes: the loss of epithelial characters 
and the gain of mesenchymal characters [4,7]. E- cadherin 
is the membrane protein working as an adhesion molecule, 
and it is the most common epithelial factor. The loss of 
E- cadherin is one of the major features of EMT [4]. In 
contrast, N- Cadherin [8], SNAIL [4, 9], TWIST [10], and 
vimentin [4, 5, 11, 12] are mesenchymal factors that work 
during various phases of EMT. Vimentin, a member of 
the intermediate filament family, is the protein responsible 
for maintaining cellular integrity and reducing damage 
caused by stress. Vimentin is expressed in normal mes-
enchymal cells, and recent studies have shown a correlation 
between increased levels of vimentin expression and ma-
lignant progression in various types of cancers, such as 
prostate, gastrointestinal, central nervous system, breast, 
malignant melanoma, and lung cancers [12].
On the other hand, the cancer stem cell was first re-
ported in 1997 by Bonnet, in human acute myeloid leu-
kemia [13]. The presence of cancer stem cells in solid 
tumors, such as breast cancer [14], colon cancer [15], 
pancreatic cancer [16], and brain tumors [17], has been 
proposed recently. Cancer stem cells are also called cancer- 
initiating cells because of their capacities for self- renewal, 
multi- lineage differentiation, and higher levels of malig-
nancy [18, 19]. Some studies have shown that cancer stem 
cells are resistant to therapy and are responsible for tumor 
recurrence and metastasis [20]. There are many reports 
in which CS markers correlated with patients’ prognoses. 
Previous reports demonstrated that CD133 expression is 
correlated with brain [21] and colon cancer [22], CD44 
is correlated with pancreatic cancer [23], and aldehyde 
dehydrogenase (ALDH) is correlated with ovarian cancers 
[24]. Some reports mentioned the presence of CS markers 
in lung cancer [25–27], but they are not definitive yet.
Previously, EMT and CS have been separately reported 
in terms of their unfavorable effects on prognosis. In in 
vitro experiments, the associations among each property 
have been reported [28], whereas their mutual associations 
in a clinical setting remain elusive.
The purposes of our present study are to elucidate the 
association between the EMT and CS and to determine 
their effect on the prognosis in lung adenocarcinoma. 
We also present the key factors that link EMT and CS 




A total of 239 specimens of lung adenocarcinomas were 
collected from patients who had undergone surgery at 
the Kyoto University Hospital from January 2001 to 
December 2007. Patients who received neoadjuvant therapy, 
underwent incurable surgery, or had multiple cancers, 
were excluded. All specimens were subjected to tissue 
microarray (TMA) analysis, as described below. The  tumors 
were staged according to the 7th edition of the TNM 
classification of the International Union Against Cancer 
[29]. Histological classification was according to the 2004 
WHO classification [30] and the IASLC/ATS/ERS clas-
sification of lung adenocarcinoma [31]. According to the 
IASLC/ATS/ERS criteria, each tumor was reviewed using 
comprehensive histologic subtyping and the percentage 
of each histologic component in 5% increments was re-
corded. The survival time and outcome data were available 
for all 239 patients, with a median follow- up time of 
63.0 months (range: 1–129 months). Approval for the 
use of the tissues in this research was obtained from the 
Institutional Review Board of Kyoto University.
Tissue microarray
TMAs were made by the pathologists in the department 
of Diagnostic Pathology in Kyoto University Hospital [32] 
using a similar approach to that described previously by 
Kononen et al. [33]. Briefly, after the case selection de-
scribed above, paraffin- embedded tumor blocks with suf-
ficient tissue were selected for TMA. The most 
representative regions of the tumors were selected based 
on the morphology of the H&E- stained slide. Tissue cores 
measuring 2 mm in diameter were punched out from 
each donor tumor block, using thin- walled stainless steel 
needles (Azumaya Medical Instruments Inc., Tokyo, Japan), 
and were arrayed in a recipient paraffin block. Non- 
neoplastic lung tissue cores from selected patients were 
also arrayed in the same block to serve as negative 
controls.
Immunohistochemical analysis
A standard immunostaining technique, which was pre-
viously published [34], was implemented in this study. 
Immunostaining against E- cadherin, vimentin, CD133, 
CD44, and ALDH was performed with mouse anti- 
human E- cadherin monoclonal antibody (36B5, dilution 
1:300, Leica Biosystems, Newcastle, UK), mouse anti- 
human vimentin monoclonal antibody (SRL33, dilution 
1:300, Leica Biosystems), mouse anti- human CD133 
monoclonal antibody (W6B3C1, dilution 1:10, Miltenyi 
Biotec, Auburn, CA), mouse anti- human CD44 mono-
clonal antibody (156- 3C11, dilution 1:50; Cell Signaling 
Technology, Danvers, MA), and rabbit anti- human 
ALDH1A1 polyclonal antibody (dilution at 1:3000, 
Abcam, Cambridge, UK). After deparaffinization and 
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rehydration, the slides were heated in a microwave for 
20 min in 10 μmol/L citrate buffer solution at pH 6.0 
(E- cadherin, vimentin, CD133, CD44), or heated by 
autoclaving for 5 min (ALDH). After quenching the 
endogenous peroxidase activity with 0.3% H2O2 in ab-
solute methanol for 30 min, the sections were treated 
with 1% horse (E- cadherin, vimentin, CD133, CD44) 
or goat (ALDH) normal serum albumin. The sections 
were incubated overnight with the primary antibodies. 
Slides were then incubated for 1 h with each equivalent 
biotinylated secondary antibody. The sections were in-
cubated with the avidin–peroxidase complex for 1 h 
and visualized with 3,3′- diaminobenzidine tetrahydro-
chloride (Dojindo laboratories, Kumamto, Japan). Lastly, 
the sections were lightly counterstained with Mayer’s 
hematoxylin. The immunostained sections were 
Figure 1. Representative images of immunohistochemical staining of lung adenocarcinoma sections with anti- E- cadherin (A and B), vimentin (C and 
D), CD133 (E and F), CD44 (G and H), and ALDH (I and J) antibodies. (A, C, E, G, and I) show positive expression, while B, D, F, H, and J show negative 
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examined by two authors (T. S. and T. M.) without 
knowledge of the patient characteristics. Cases with 
discrepancies were jointly reevaluated until a consensus 
was reached. After immunostaining, the expressions of 
these proteins were examined in four distinct fields 
with a minimum of 500 cells. The proportion of posi-
tive cells was measured and classified as 0 (no staining), 
+1 (weak), +2 (moderate), and +3 (strong), and each 
specimen was categorized as negative (0, +1) or posi-
tive (+2, +3). Figure 1 shows representative images of 
immunohistochemical staining by anti E- cadherin (A, 
B), vimentin (C, D), CD133 (E, F), CD44 (G, H), and 
ALDH (I, J) antibodies.
Statistical analysis
Age and average smoking index were summarized using 
the mean ± SD, whereas the categorical variables were 
summarized using counts and percentages. The OS (overall 
survival) was calculated from the date of surgery. Time- 
to- event curves for OS were estimated using the Kaplan–
Meier method, and differences in time- to- event curves 
were evaluated with the log- rank test. The correlations 
among the five markers were analyzed using odds ratio 
and chi- square tests. The analysis of the hazard ratio was 
performed using the Cox proportional hazards regression 
analysis. All P- values were two- sided and P- values <0.05 
were considered statistically significant. All statistical analy-




The clinicopathological characteristics of the patients and 
tumors evaluated in our study are summarized in Table 1. 
There were 123 (51.5%) men, with a mean age of 
67.0 ± 9.6 years (range, 23–86 years). One hundred and 
nine patients (45.6%) had never smoked, and 130 patients 
(54.3%) were former or current smokers, with an average 
smoking index of 26.5 ± 36.4 pack- years. The numbers 
of patients at each pathological stage were as follows: IA, 
119 (49.8%); IB, 70 (29.3%); IIA, 22 (9.2%); IIB, 4 (1.7%); 
IIIA, 23 (9.6%) patients; and IIIB, 1 (0.4%) (Table 1). 
There were 189 (79.1%) pathological stage I cases in this 
study, which is higher than that generally reported. The 
frequency of EMT or CS marker expressions is shown 
in Table 2. The analysis of TMA specimens for EMT and 
CS markers indicated that of the 239 cases, 120 (50.2%) 
specimens were positive for E- cadherin, 50 (20.9%) for 
vimentin, 26 (10.9%) for CD133, 48 (20.1%) for CD44, 
and 89 (37.2%) for ALDH, respectively.
Relationship between EMT markers and 
patient prognosis
The prognoses of patients depending on EMT markers 
are shown in Figures 2A and B. The negative 
 E- cadherin group and the positive vimentin group 
had significantly poorer prognoses (Fig. 2A and B, 
P = 0.003 and P = 0.005, respectively). The prognoses 
of patients depending on the combination of EMT 
markers are shown in Figure 2C. These data suggest 
that the null EMT conversion group (positive E- cadherin 
and negative vimentin) had the best prognosis, and 
that patients with EMT progression indicated a worse 
prognosis.
Table 1. Characteristics of the patients included in this study.
Variables N = 239
Sex, n (%)
 Male 123 (51.5)
 Female 116 (48.5)
Age (years), 67.0 ± 9.6 years old
Smoking status
 Never 109 (45.6%)
 Former/current 130 (54.3%)
 Average smoking index 26.5 ± 36.4 pack- years
p- Stage (%)
 IA 119 (49.8)
 IB 70 (29.3)
 IIA 22 (9.2)
 IIB 4 (1.7)
 IIIA 23 (9.6)
 IIIB 1 (0.4)
Tumor grade (%)
 Well differentiated 47 (19.7)
 Moderately differentiated 97 (40.6)
 Poorly differentiated 95 (39.8)
Lymphatic invasion (%)
 Absent 193 (80.8)
 Present 46 (19.3)
Vascular invasion (%)
 Absent 184 (77.0)
 Present 55 (23.0)
Pleural invasion (%)
 pl 0 188 (78.7)
 pl 1- 3 51 (21.3)
IASLC/ATS/ERS classification of lung adenocarcinoma (%)
 Adenocarcinoma in situ 9 (3.8)
 Minimally invasive adenocarcinoma 13 (5.4)
 Lepidic predominant 18 (7.5)
 Acinar predominant 31 (13.0)
 Papillary predominant 111 (46.4)
 Micropapillary predominant 8 (3.4)
 Solid predominant 41 (17.2)
 Invasive mucinous adenocarcinoma 7 (2.9)
 Others 1 (0.4)
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Relationship between CS markers and 
patient prognosis
The prognoses affected by CS markers are shown 
in Figure 3A, B, and C. The expression of CD133 had a 
significantly unfavorable effect on prognosis (Fig. 3A, 
P < 0.001). However, the expression of CD44 and 
ALDH did not significantly correlate with the progno-
sis of the patients (Fig. 3B and C, P = 0.427 
and P = 0.911, respectively). In our study, CD133 is 
the only prognostic factor of CS among these 
markers.
Association among EMT and CS markers in 
lung adenocarcinoma
The association between EMT and CS markers is shown in 
Figure 4. A negative correlation was found between E- cadherin 
and vimentin expression (P < 0.001), whereas, a positive 
correlation was found between vimentin and CD133 expres-
sion (P = 0.020). Only CD133 was significantly correlated 
with EMT markers rather than the other CS markers.
The expressions of the EMT marker vimentin and the 
CS marker CD133 showed significant correlation, suggesting 
that these factors are the key factors linking EMT and CS.
Table 2. Expressions of EMT and CS markers in the specimens.
E- cadherin Vimentin CD133 CD44 ALDH
Positive 120 (50.2%) 50 (20.9%) 26 (10.9%) 48 (20.1%) 89 (37.2%)
Negative 119 (49.8%) 189 (79.1%) 213 (89.1%) 191 (79.9%) 149 (62.3%)
One specimen could not be evaluated for its ALDH expression, because the specimen was insufficient in the tissue microarray slide. EMT, epithelial- 
mesenchymal transition; CS, cancer stemness; ALDH, aldehyde dehydrogenase.
Figure 2. Kaplan–Meier curves for overall survival and log- rank P values according to EMT markers. (A) E- cadherin, (B) vimentin, and (C) combination 
of EMT markers. (E+) E- cadherin positive, (E−) E- cadherin negative, (V+) vimentin positive, and (V−) vimentin negative, EMT, epithelial- mesenchymal 
transition.
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Effects of EMT and CS markers on patient 
prognosis of lung adenocarcinoma in 
multivariate analysis
We analyzed the effects of the expressions of CD133 
and EMT markers on OS. Because CD133 was the 
strongest prognostic marker, as shown in Figure 3A, we 
divided the patients into positive or negative CD133 
groups. In the positive CD133 group, there were no 
clear differences in the Kaplan–Meier curves for OS 
among the subgroups with EMT progression. Since only 
26 patients were included in this group, we combined 
them into one group for an additional analysis (Table 3, 
CD133+). Regarding the negative CD133 group, we 
 classified this group into three groups, based on the 
expression of E- cadherin and vimentin, as follows: full 
EMT conversion group, E- cadherin- negative and 
vimentin- positive; partial EMT conversion group, both 
E- cadherin- and vimentin- negative or positive; and null 
EMT conversion group, E- cadherin- positive and 
vimentin- negative.
In Figure 5, there were clear differences in the Kaplan–
Meier curves for OS among the negative CD133 groups 
divided by the progression of EMT. The group indicating 
negative CD133 and null EMT conversion showed the 
best prognosis.
Table 3 shows the results of a Cox regression analysis 
adjusted for covariates (p- stage, sex, and age). As com-
pared with the negative CD133 and null EMT conversion 
group, the hazard ratios (P- values) of the positive CD133 
group, negative CD133 and full EMT conversion group, 
and negative CD133 and partial EMT conversion group 
were 3.56 (P = 0.002), 1.90 (P = 0.127), and 2.07 
(P = 0.038), respectively. The positive CD133 group showed 
the worst prognosis (P = 0.002).
Discussion
Importantly, our research shows the effects of EMT and 
CS on patients’ prognoses and a clear association between 
EMT and CS in clinical specimens. The EMT marker 
Figure 3. Kaplan–Meier curves for overall survival and log- rank P values according to CS markers. (A) CD133, (B) CD44, and (C) ALDH. ALDH, 
aldehyde dehydrogenase; CS, cancer stemness.
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vimentin and CS marker CD133 will be focused on as 
the key factors linking EMT with CS.
EMT and CS have been reported to affect migration, 
invasion, metastasis, and therapeutic resistance [4, 6, 20]. 
Surprisingly, there are few reports referring to the as-
sociation of EMT and CS. In an in vitro study, Mani 
et al. reported that EMT- induced normal epithelial mam-
mary cells obtained the characteristics of CS including 
CD133 expression [28]. Pirozzi et al. also reported that 
the EMT- induced cancer cell line A549 acquired CS [35]. 
In clinical reports, there have been many articles about 
each marker, but the associations between EMT and CS 
have not been reported previously. Our study revealed 
that vimentin and CD133 expression are correlated, and 
that the CS marker CD133 is associated with a worse 
prognosis than EMT conversion.
However, it remains unclear how vimentin and CD133 
affected the prognoses in our report. CD133 is a five- 
transmembrane cell surface glycoprotein family, and its 
gene, PROM1 is specifically located on chromosome 4p15, 
a region that contains genes related to mature organ 
 homoeostasis, tumorigenesis, and cancer progression [36]. 
Previous studies have determined that positive CD133 
cancer cells possess CS [36], but its precise function  remains 
unclear. Tirino et al. investigated the role of CD133 by 
analyzing the differences between positive and negative 
CD133 subpopulations in the lung cancer cell line A549 
[37]. The positive CD133 subpopulation expressed vimentin 
more strongly and had more potential for invasion, mi-
gration, and distant metastasis than the negative CD133 
one. These data are compatible with our results; that is, 
there is correlation between the expression of CD133 and 
vimentin, and the group with positive CD133 expression 
had a worse prognosis. Although the major roles of CD133 
remain unidentified, we have shown that CD133 has an 
important role in tumor progression in lung 
adenocarcinoma.
EMT progression was not an independent prognostic 
marker in our multivariate analysis (Table 3). EMT pro-
gression (full/partial/null) was significantly correlated with 
pathological stage (stage I/II, III) in our study (data not 
shown). This fact might have some effects on this result. 
Conversely, it is suggested that EMT correlates with T 
or N factors, which is very interesting.
Cancer, including lung adenocarcinoma, has been dif-
ficult to treat. The characteristics of the EMT and CS 
have been widely investigated, but EMT and CS have 
Figure 4. Association among EMT and CS markers. EMT, epithelial- 
mesenchymal transition; CS, cancer stemness; ALDH, aldehyde 
dehydrogenase; OR, odds ratio.
Table 3. The Cox proportional hazards regression analysis for EMT and 
CS markers (adjustment factors: p- stage, sex, age).
Parameter Hazard ratio 95% CI P- value
CD133+ 3.56 [1.62–7.81] 0.002
CD133− & Full EMT 1.90 [0.83–4.32] 0.127
CD133− & Partial EMT 2.07 [1.04–4.24] 0.038
CD133− & Null EMT 
(Reference)
1
p- stage [II, III/I] 6.38 [3.61–11.4] <0.001
Sex [male/female] 1.58 [0.92–2.80] 0.099
Age 1.03 [1.00–1.06] 0.073
The hazard ratios of groups stratified by CD133 expression and EMT 
progression are shown in Table 3. Since only 26 patients were included 
in the CD133 positive group, we combined them into one group for this 
analysis (CD133+). These hazard ratios are standardized with that of the 
CD133− and null EMT conversion group. CI, confidence interval; EMT, 
epithelial- mesenchymal transition; CS, cancer stemness.
Figure 5. Kaplan–Meier curves for overall survival of the groups of 
CD133- negative patients divided by the progression of EMT. Three 
groups of CD133- negative patients are shown based on the expression 
of E- cadherin and vimentin as follows; full EMT conversion group, 
E- cadherin- negative and vimentin- positive; partial EMT conversion 
group, both E- cadherin- and vimentin- negative or positive; null EMT 
conversion group, E- cadherin- positive and vimentin- negative. EMT, 
epithelial- mesenchymal transition.
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not been examined enough as therapeutic targets. Since 
the expressions of vimentin and CD133 are correlated, 
targeting CS via EMT may be possible. For example, 
silibinin was reported to inhibit tumor progression via 
vimentin and MMP- 2 suppression [38, 39], and salino-
mycin was reported to lead to the regression of cancer 
via the suppression of the EMT and CS marker, CD133 
[40]. Our study supports these previous reports and shows 
the possibility of their application for clinical therapy.
It is necessary to understand the common background 
mechanisms underlying EMT and CS. The reports that 
transforming growth factor beta- induced EMT and CS 
in an in vitro study [28, 35] suggest the probability that 
the tumor microenvironment including cancer–associated 
fibroblasts influence the EMT and CS. In addition, hypoxia 
is also reported to induce EMT and CS via the upregulation 
of hypoxia- inducible factor 1α expression [41, 42]. These 
mechanisms may underlie the results of the present study. 
Interventions targeting these factors will be necessary 
for the innovative therapy of lung cancer. Moreover, the 
associations of EMT or CS with pathological 
characteristics or genetic alternations are not definitive 
in lung cancer [43, 44]. The analyses of these factors 
are now underway in our group, and they will also be 
useful to unveil the nature of EMT and CS.
There are some limitations to our study. First, the pro-
portion of stage I cases in our study is 79.1%, and it is 
larger than what has generally been reported [45]. This 
is because patients receiving neoadjuvant therapy, undergo-
ing incurable surgery, and those with multiple cancers were 
excluded to ensure accurate evaluation of the association 
between these biomarkers and prognoses. It is possible 
that this fact had some effect on our results. Second, the 
expression of CD44 was detected using a mouse anti- 
human CD44 monoclonal antibody (pan- CD44), and it 
was not prognostic in our study. Regarding CD44, both 
pan- CD44 and its variant CD44v6 were reported to be 
prognostic [26]. It is not yet definitive which splice variant 
is more prognostic, and further investigation will be needed.
In conclusion, we showed that the progression of EMT 
and the expression of the CS marker CD133 had signifi-
cantly unfavorable effects on the prognoses of lung adeno-
carcinoma patients. The EMT and CS were significantly 
correlated through vimentin and CD133. The CS marker 
CD133 was a stronger prognostic factor than the EMT 
markers. Further research into these factors is expected to 
elucidate how cancers acquire metastatic potency and resist-
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